Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: Conceptual framework and therapeutic potential
Authors: Jean Charles Fruchart
Raul D. Santos
Carlos Aguilar-Salinas
Masanori Aikawa
Khalid Al Rasadi
Pierre Amarenco
Philip J. Barter
Richard Ceska
Alberto Corsini
Jean Pierre Després
Patrick Duriez
Robert H. Eckel
Marat V. Ezhov
Michel Farnier
Henry N. Ginsberg
Michel P. Hermans
Shun Ishibashi
Fredrik Karpe
Tatsuhiko Kodama
Wolfgang Koenig
Michel Krempf
Soo Lim
Alberto J. Lorenzatti
Ruth McPherson
Jesus Millan Nuñez-Cortes
Børge G. Nordestgaard
Hisao Ogawa
Chris J. Packard
Jorge Plutzky
Carlos I. Ponte-Negretti
Aruna Pradhan
Kausik K. Ray
Zeljko Reiner
Paul M. Ridker
Massimiliano Ruscica
Shaukat Sadikot
Hitoshi Shimano
Piyamitr Sritara
Jane K. Stock
Ta Chen Su
Andrey V. Susekov
André Tartar
Marja Riitta Taskinen
Alexander Tenenbaum
Lale S. Tokgözoǧlu
Brian Tomlinson
Anne Tybjærg-Hansen
Paul Valensi
Michal Vrablík
Walter Wahli
Gerald F. Watts
Shizuya Yamashita
Koutaro Yokote
Alberto Zambon
Peter Libby
INRA Pays de la Loire
Hospital y CRS El Pino
Jichi Medical University
Seoul National University Bundang Hospital
Sultan Qaboos University Hospital
National Medical Research Center of Cardiology, Moscow
Hospital General Universitario Gregorio Marañon
Université Laval
University of Western Australia
Københavns Universitet
Centre Hospitalier Universitaire de Dijon
Università degli Studi di Milano
Jaslok Hospital and Research Centre
University of Helsinki Faculty of Medicine
University of New South Wales (UNSW) Australia
Universidad Complutense de Madrid
University of Oxford
Hôtel Dieu CHU de Nantes
University of Tokyo
Osaka University
Hacettepe Üniversitesi
Instituto do Coracao do Hospital das Clinicas
Brigham and Women's Hospital
Charles University
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Imperial College London
Amtssygehuset i Gentofte
University of Tsukuba
Cliniques Universitaires Saint-Luc
Chaim Sheba Medical Center Israel
University of Ottawa Heart Institute
Vagelos College of Physicians and Surgeons
Universität Ulm
University of Colorado Health Sciences Center
Universite Paris 13
Instituto Nacional de la Nutrición Salvador Zubiran
Deutsches Herzzentrum München
University of Zagreb School of Medicine
Universite Paris 7- Denis Diderot
Nanyang Technological University
National Taiwan University
Tel Aviv University, Sackler Faculty of Medicine
Boston Medical Center
Hopital G. et R. Laennec CHU de Nantes
Chinese University of Hong Kong
Chiba University
Harvard Medical School
University of Glasgow
Escuela de Medicina y Ciencias de la Salud TecSalud
INRA Occitanie-Toulouse
Università degli Studi di Padova
Université Lille 2 Droit et Santé
Université de Lausanne (UNIL)
R3i Foundation
DAMIC Medical Institute/Rusculleda Foundation for Research
Russian Medical Academy for Postgraduate Education
National Cerebral and Cardiovascular Center
Rinku General Medical Center
Keywords: Medicine
Issue Date: 4-Jun-2019
Citation: Cardiovascular Diabetology. Vol.18, No.1 (2019)
Abstract: © 2019 The Author(s). In the era of precision medicine, treatments that target specific modifiable characteristics of high-risk patients have the potential to lower further the residual risk of atherosclerotic cardiovascular events. Correction of atherogenic dyslipidemia, however, remains a major unmet clinical need. Elevated plasma triglycerides, with or without low levels of high-density lipoprotein cholesterol (HDL-C), offer a key modifiable component of this common dyslipidemia, especially in insulin resistant conditions such as type 2 diabetes mellitus. The development of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) offers an approach to address this treatment gap. This Joint Consensus Panel appraised evidence for the first SPPARMα agonist and concluded that this agent represents a novel therapeutic class, distinct from fibrates, based on pharmacological activity, and, importantly, a safe hepatic and renal profile. The ongoing PROMINENT cardiovascular outcomes trial is testing in 10,000 patients with type 2 diabetes mellitus, elevated triglycerides, and low levels of HDL-C whether treatment with this SPPARMα agonist safely reduces residual cardiovascular risk.
ISSN: 14752840
Appears in Collections:Scopus 2019

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.